CN104402800A - 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法 - Google Patents

一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法 Download PDF

Info

Publication number
CN104402800A
CN104402800A CN201410713716.6A CN201410713716A CN104402800A CN 104402800 A CN104402800 A CN 104402800A CN 201410713716 A CN201410713716 A CN 201410713716A CN 104402800 A CN104402800 A CN 104402800A
Authority
CN
China
Prior art keywords
fluorophenyl
trans
preparation
methylol
press filtration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410713716.6A
Other languages
English (en)
Inventor
杨会来
毛杰
孙学喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wan Hui Pharmaceutical (anhui) Co Ltd
Original Assignee
Wan Hui Pharmaceutical (anhui) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wan Hui Pharmaceutical (anhui) Co Ltd filed Critical Wan Hui Pharmaceutical (anhui) Co Ltd
Priority to CN201410713716.6A priority Critical patent/CN104402800A/zh
Publication of CN104402800A publication Critical patent/CN104402800A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,是通过对氟苯甲醛和磷酰基乙酸三乙酯反应生成4-氟肉桂酸乙酯,4-氟肉桂酸乙酯再与N-甲胺基羰基乙酸乙酯反应生成环合物哌啶二酮,环合物哌啶二酮最后与四氢呋喃、硼氢化钾和三氟化硼乙醚反应三氟化硼乙醚生成产品。本发明制备的反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶质量好,纯度高,制备方法简单,能耗少,成本低。

Description

一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法
 
技术领域
   本发明涉及药品制造领域,具体是一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法。
背景技术
反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶,用作药物帕罗西汀中间体。帕罗西汀(Paroxetine)是一种选择性血清素再吸收抑制剂(SSRI)型的抗抑郁药,其药物形态为盐酸帕罗西汀(Paroxetine hydrochloride),商品名为“赛乐特”(Seroxat)。在临床上常用于抑郁症和强迫症的治疗。
发明内容
本发明要解决的技术问题是提供一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,其成本低,收率高。
本发明的技术方案为:
一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,包括如下步骤:
(1)、首先将无水乙醇和氢氧化钾加入到反应容器中,然后在温度20-25℃下滴加对氟苯甲醛和磷酰基乙酸三乙酯混合液,滴加完毕保温反应13小时,反应液压滤除去固体物质,然后常压蒸馏回收乙醇,残液冷却到室温,加甲苯和水后搅拌静置分水,甲苯层干燥、压滤、蒸馏得4-氟肉桂酸乙酯;
(2)、先将无水乙醇和N-甲胺基羰基乙酸乙酯加入到反应容器中,然后在-15—5℃滴加乙醇钠的乙醇溶液,然后继续滴加4-氟肉桂酸乙酯和无水乙醇混合物,保温13小时,调节PH为5—6,冷冻,粗品析出,离心得环合物哌啶二酮粗品;
(3)、先将四氢呋喃和硼氢化钾加入到反应容器中,然后在35℃滴加环合物哌啶二酮和四氢呋喃/乙醇混合液, 然后在l5℃以下滴加三氟化硼乙醚/四氢呋喃混合液,滴毕于28℃保温反应15h结束反应,冷却到-10℃,然后滴加到盐酸中,搅拌3—4小时,压滤、滤液蒸馏,残余物加二甲苯和水于80℃温热分层,二甲苯层萃取,调节PH=9,再经搅拌、静置、分水,甲苯层干燥、压滤,滤液蒸馏,用石油醚重结晶、离心、烘干得反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶。
所述的步骤(1)中对氟苯甲醛和磷酰基乙酸三乙酯的质量比为1 :1.3—1.4。
所述的步骤(2)中4-氟肉桂酸乙酯和N-甲胺基羰基乙酸乙酯的质量比为1 :0.85—0.9。
所述的步骤(2)中环合物哌啶二酮粗品加入到丙酸甲酯溶解、冷却、水洗、静置分出水层萃取,有机层干燥、压滤,滤液蒸馏、抽真空,最后加入正丁醇过滤、冷却、结晶、离心,得到精品环合物哌啶二酮。
本发明的优点:
本发明制备的反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶质量好,纯度高,制备方法简单,能耗少,成本低。
具体实施方式
一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,包括如下步骤:
(1)、首先将28g无水乙醇和3.5g氢氧化钾加入到反应容器中,然后在温度20-25℃下滴加6.4g对氟苯甲醛和8.5g磷酰基乙酸三乙酯混合液,滴加完毕保温反应13小时,瓶内有固体盐产生,反应液压滤除去固体物质,常压蒸馏回收乙醇,残液冷却到室温,加甲苯15ml,水30ml搅拌静置分水,甲苯层加入2g无水硫酸钠干燥,再压滤到甲苯蒸馏瓶中蒸馏得4-氟肉桂酸乙酯;
(2)、先将10ml无水乙醇和6.2g N-甲胺基羰基乙酸乙酯加入到反应容器中,然后在-15—5℃滴加乙醇钠的乙醇溶液(0.8g钠、5ml无水乙醇),然后继续滴加7.1g 4-氟肉桂酸乙酯和10ml无水乙醇混合物,保温13小时,用6g乙酸调节pH为5.5,冷冻,粗品析出,离心得环合物哌啶二酮粗品;环合物哌啶二酮粗品加入到15ml丙酸甲酯溶解、冷却、加12ml水洗、静置分出水层到分液漏斗中用25ml丙酸甲酯萃取,分出水层弃去,有机层中加入无水硫酸钠干燥、压滤,滤液蒸馏回收丙酸甲酯套用,其它部分抽真空除尽丙酸甲酯,最后加入正丁醇过滤、冷却、结晶、离心,得到精品环合物哌啶二酮;
(3)、先将22.5ml四氢呋喃和2.8g硼氢化钾加入到反应容器中,然后在35℃滴加5g环合物哌啶二酮和12ml四氢呋喃/乙醇混合液(体积比1:4), 然后在l5℃以下滴加6ml三氟化硼乙醚/5ml四氢呋喃混合液,滴毕于28℃保温反应15h结束反应,冷却到-10℃,然后滴加到4ml 25%盐酸中,搅拌3—4小时,压滤、滤液蒸馏,残余物加l0ml二甲苯和l5ml水于80℃温热分层,二甲苯层用10ml水萃取,合并水层,二甲苯层中再加入10ml二甲苯,滴加20%碱液调节pH=9,再经搅拌、静置、分水,甲苯层干燥、压滤,滤液蒸馏,用石油醚重结晶、离心、烘干得反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶,含量98.57%,收率87.2l%;
。 

Claims (4)

1.一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,其特征在于:包括如下步骤:
(1)、首先将无水乙醇和氢氧化钾加入到反应容器中,然后在温度20-25℃下滴加对氟苯甲醛和磷酰基乙酸三乙酯混合液,滴加完毕保温反应13小时,反应液压滤除去固体物质,然后常压蒸馏回收乙醇,残液冷却到室温,加甲苯和水后搅拌静置分水,甲苯层干燥、压滤、蒸馏得4-氟肉桂酸乙酯;
(2)、先将无水乙醇和N-甲胺基羰基乙酸乙酯加入到反应容器中,然后在-15—5℃滴加乙醇钠的乙醇溶液,然后继续滴加4-氟肉桂酸乙酯和无水乙醇混合物,保温13小时,调节PH为5—6,冷冻,粗品析出,离心得环合物哌啶二酮粗品;
(3)、先将四氢呋喃和硼氢化钾加入到反应容器中,然后在35℃滴加环合物哌啶二酮和四氢呋喃/乙醇混合液, 然后在l5℃以下滴加三氟化硼乙醚/四氢呋喃混合液,滴毕于28℃保温反应15h结束反应,冷却到-10℃,然后滴加到盐酸中,搅拌3—4小时,压滤、滤液蒸馏,残余物加二甲苯和水于80℃温热分层,二甲苯层萃取,调节PH=9,再经搅拌、静置、分水,甲苯层干燥、压滤,滤液蒸馏,用石油醚重结晶、离心、烘干得反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶。
2.根据权利要求1所述的一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,其特征在于:所述的步骤(1)中对氟苯甲醛和磷酰基乙酸三乙酯的质量比为1 :1.3—1.4。
3.根据权利要求1所述的一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,其特征在于:所述的步骤(2)中4-氟肉桂酸乙酯和N-甲胺基羰基乙酸乙酯的质量比为1 :0.85—0.9。
4.根据权利要求1所述的一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法,其特征在于:所述的步骤(2)中环合物哌啶二酮粗品加入到丙酸甲酯溶解、冷却、水洗、静置分出水层萃取,有机层干燥、压滤,滤液蒸馏、抽真空,最后加入正丁醇过滤、冷却、结晶、离心,得到精品环合物哌啶二酮。
CN201410713716.6A 2014-12-02 2014-12-02 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法 Pending CN104402800A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410713716.6A CN104402800A (zh) 2014-12-02 2014-12-02 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410713716.6A CN104402800A (zh) 2014-12-02 2014-12-02 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法

Publications (1)

Publication Number Publication Date
CN104402800A true CN104402800A (zh) 2015-03-11

Family

ID=52640482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410713716.6A Pending CN104402800A (zh) 2014-12-02 2014-12-02 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法

Country Status (1)

Country Link
CN (1) CN104402800A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892491A (zh) * 2015-05-06 2015-09-09 浙江海森药业有限公司 一种合成帕罗西汀手性中间体的方法
CN109020872A (zh) * 2018-06-26 2018-12-18 浙江邦富生物科技有限责任公司 一种盐酸帕罗西汀关键中间体的制备方法
WO2022269643A1 (en) * 2021-06-25 2022-12-29 Vihita Chem Private Limited An improved process for the preparation of intermediate for paroxetine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902801A (en) * 1985-08-10 1990-02-20 Beecham Group Plc. Process for preparing aryl-piperidine carbinols and novel intermediates used in the process
WO1997044320A1 (en) * 1996-05-24 1997-11-27 Fmc Corporation Improved processes for the reduction of imide ester functionality
US20020082277A1 (en) * 2000-05-12 2002-06-27 Lemmens Jacobus M. Tosylate salts of 4-(p-fluorophenyl)-piperidine -3-carbinols
CN101360742A (zh) * 2005-11-14 2009-02-04 奥斯拜客斯制药有限公司 具有血清素源性活性和增强的治疗特性的取代苯基哌啶

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902801A (en) * 1985-08-10 1990-02-20 Beecham Group Plc. Process for preparing aryl-piperidine carbinols and novel intermediates used in the process
WO1997044320A1 (en) * 1996-05-24 1997-11-27 Fmc Corporation Improved processes for the reduction of imide ester functionality
US20020082277A1 (en) * 2000-05-12 2002-06-27 Lemmens Jacobus M. Tosylate salts of 4-(p-fluorophenyl)-piperidine -3-carbinols
CN101360742A (zh) * 2005-11-14 2009-02-04 奥斯拜客斯制药有限公司 具有血清素源性活性和增强的治疗特性的取代苯基哌啶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王一军,等: "(-)反式-4R(4-氟苯基)-3S-羟甲基-1-甲基哌啶的合成", 《精细化工中间体》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892491A (zh) * 2015-05-06 2015-09-09 浙江海森药业有限公司 一种合成帕罗西汀手性中间体的方法
CN104892491B (zh) * 2015-05-06 2017-05-17 浙江海森药业有限公司 一种合成帕罗西汀手性中间体的方法
CN109020872A (zh) * 2018-06-26 2018-12-18 浙江邦富生物科技有限责任公司 一种盐酸帕罗西汀关键中间体的制备方法
CN109020872B (zh) * 2018-06-26 2020-05-12 浙江邦富生物科技有限责任公司 一种盐酸帕罗西汀关键中间体的制备方法
WO2022269643A1 (en) * 2021-06-25 2022-12-29 Vihita Chem Private Limited An improved process for the preparation of intermediate for paroxetine

Similar Documents

Publication Publication Date Title
CN103739504B (zh) 一种重酒石酸间羟胺的合成方法
CN104402800A (zh) 一种反式-4-(4-氟苯基)-3-羟甲基-1-甲基哌啶的制备方法
CN104478839A (zh) 一种达格列净的合成方法
CN103288801B (zh) 一种高纯度埃索美拉唑钠的制备方法
CN103342664A (zh) 酒石酸盐的制备方法
CN104193643B (zh) 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN103864630A (zh) (s)-1-(4-乙氧基苄基)-3-氮杂戊烷-1,5-二胺三盐酸盐的合成方法
CN101481333B (zh) 一种新的卡巴拉汀制备方法
CN100494153C (zh) 八角莽草酸提取分离技术
CN102659863B (zh) 一种四羟基二苯乙烯苷的分离纯化工艺
CN102603594B (zh) (s)-奥拉西坦的制备方法
CN105440030B (zh) 一种胆碱m受体拮抗剂阿地溴铵及其制备方法
CN104628625A (zh) 一种N-boc-4-羟基哌啶合成方法
CN102898289B (zh) 一种医药中间体 2-(4-苯甲氧基苯基)乙醇的合成方法
CN102070624B (zh) 一种盐酸噻加宾的合成方法及无水盐酸噻加宾的制备方法
CN102350091B (zh) 一种用复合萃取剂分离脂肪酸植物甾醇酯粗产品的方法
CN104230882B (zh) 一种度洛西汀盐酸盐杂质的制备方法
CN105348279A (zh) 一种r-2,2-二(2-噻吩基)-2-羟基乙酸奎宁-3-基酯及其制备和应用
CN103102316A (zh) ZD1839Form 1晶型的制备方法
CN104861025A (zh) 醋酸乌利司他的纯化方法
CN103319358B (zh) 一种7-氨基庚酸的制备方法
CN105085321B (zh) 一种n‑甲氧羰基‑l‑叔亮氨酸的制备方法
CN102993144B (zh) 4-氨基四氢吡喃的一锅法合成工艺
CN105523984B (zh) (1r,2s)-1-苯基-2-(1-吡咯烷基)-1-丙醇的制备方法
CN102702280B (zh) 1,6-酐-2-叠氮-2-去氧-4-O-对甲氧苄基-β-D-吡喃葡萄糖苷的提纯方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150311